Floatz logo

Vortioxetine

Cognitive Change

Brain and Cognition Discovery FoundationSmall moleculePhase 2/3Dormant
B
61/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
46/ 100
Competitive Position
95/ 100

Competitive context

6 Active assets in the Cognitive Change cohort.

Asset / SponsorPhaseRating
Namenda
UNC Lineberger Comprehensive Cancer Center
Phase 4BB
DESVENLAFAXINE
David Steffens
Phase 4BB
Wellbutrin
David Steffens
Phase 4BB
Sertraline
David Steffens
Phase 4BB
CHLOROPTIC-P S.O.P. COMPONENT PREDNISOLONE
Haukeland University Hospital
Phase 2CCC

View all 10 →

Same molecule, other indications

Vortioxetine is also rated in:

major depressive disorderDormant
BBB
Indicative ·
75 / 100
View asset →
bipolar depressionDormant
BB
Indicative ·
69 / 100
View asset →
anxiety disorderDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →